Beam Therapeutics is trading 4.74% down at $23.21 after Anthropic reported that Claude identified a previously unknown CRISPR-like enzyme system, raising concerns about future competition and the durability of existing technology advantages.
- Peer gene-editing shares also declined, while biotechnology fell 2.04% during the September 24, 2026 session.
- Treasury yields and inflation concerns added pressure to growth-oriented biotechnology stocks; no separate company-specific announcement was identified.